Arca
Skip to content
Tools
Tools

NTRK3: NT-3 growth factor receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Receptor tyrosine kinase involved in nervous system and probably heart development.

  • Drugs that act on it: 4
  • Approved: 1
  • In phases 1 to 3: 3
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on NTRK3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved1

  • Repotrectinib

Phase 31

  • Lestaurtinib

Phase 20

    Phase 12

    • AZD-7451
    • PLX-7486

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule375%
    • Other125%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: NT-3 growth factor receptor inhibitor.
    RepotrectinibApprovedBristol-Myers SquibbSmall moleculeInhibitor—8—
    LestaurtinibPhase 3Teva Pharmaceutical IndustriesSmall moleculeInhibitor—0—
    AZD-7451Phase 1—Small moleculeInhibitor—0—
    PLX-7486Phase 1PlexxikonOtherInhibitor—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
    Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanRepotrectinib—RecruitingBristol-Myers Squibb2026-08-10
    Repotrectinib Post-Marketing Surveillance in Korean Patients With ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) or Solid Tumors Harboring a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene FusionRepotrectinib—Not yet recruitingBristol-Myers Squibb2026-05-20
    Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRepotrectinibPhase 2RecruitingCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer2024-08-13
    Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRepotrectinibPhase 2RecruitingMedSIR2024-03-18
    A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)RepotrectinibPhase 3Active, not recruitingBristol-Myers Squibb2023-11-20
    A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRepotrectinibPhase 1 / Phase 2RecruitingMemorial Sloan Kettering Cancer Center2021-08-13
    A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.2019-09-19
    A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRepotrectinibPhase 1 / Phase 2RecruitingTurning Point Therapeutics, Inc.2017-03-28

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Cancer
    0.67
    Neoplasm
    0.65
    Non-small cell lung carcinoma
    0.65
    Neurodegenerative disease
    0.48
    Smoking initiation
    0.40
    Thyroid gland papillary carcinoma
    0.40
    Congenital fibrosarcoma
    0.40
    Congenital mesoblastic nephroma
    0.38
    Ganglioglioma
    0.38
    Lung carcinoma
    0.37

    Genes and Related Targets

    Complexes and families that share a gene with this target
    Genes
    NTRK3

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5608, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q16288, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.